Jing Liao

Company: Alexion Pharmaceuticals

Job title: Head of Vector Technology

Bio:

Jing Liao is Head of Vector Technology at Alexion Pharmaceuticals. Her team is focusing on capsid engineering to improve the properties of the capsids. She is also leading gene editing platform development to apply novel gene editing tools to indications, plasmid optimization and cell line engineering to increase AAV manufacturability.

Seminars:

AAV Capsid Engineering to Modify the Immune Response 9:30 am

Which capsid components are predictive of a negative immune response? Presenting a capsid engineering approach to dampen innate and adaptive immune responses Outlining engineering methodology to derive the novel capsid variant Analyzing In vivo performance and addressing human translatability challengesRead more

day: Conference Day One

Panel Discussion: Developing Robust, Clinical Stage-Ready CMC Processes 3:00 pm

Ensuring vector design and selection is optimized for future manufacturing needs Discussing cost-effectiveness vector development strategies to improve yields and quality of novel vector platforms Weighing up whether to develop in-house manufacturing capabilities or outsource Outlining what good teamwork with process development and CMC teams looks likeRead more

day: Conference Day Two